Exelixis reported $647.17M in Cash and Equivalent for its fourth fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US $ 203.13M 197.1M
AstraZeneca AZN:LN 6329M 738M
Bayer BAYN:GR € 4564M 248M
Bluebird Bio BLUE:US $ 396.62M 5.84M
Cytokinetics CYTK:US $ 115.42M 2.76M
Eisai 4523:JP Y 258420M 24582M
Genmab GEN:DC DK 9071M 114M
Immunogen IMGN:US $ 437.66M 41.09M
IONIS PHARMACEUT IONS:US $ 2115M 1482.05M
Mirati Therapeutics MRTX:US $ 293.42M 100.32M
Nektar Therapeutics NKTR:US $ 25.22M 28.8M
Novartis NOVN:VX SF 12407M 5196M
Xencor XNCR:US $ 78.27M 65.21M